Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 symbols : Ions save search
Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study
Published: 2022-07-11 (Crawled : 12:00) - biospace.com/
IONS | $41.585 0.08% 0.08% 1.1M
|
Health Technology
|
| O: 0.94%
H: 1.28%
C: -0.35%
treatment rare disease kidney study phase 3
Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
Published: 2022-06-21 (Crawled : 07:00) - prnewswire.com
IONS | $41.585 0.08% 0.08% 1.1M
|
Health Technology
|
| O: 5.44%
H: 0.0%
C: 0.0%
eplontersen phase 3
Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
Published: 2022-06-03 (Crawled : 11:00) - biospace.com/
IONS | $41.585 0.08% 0.08% 1.1M
|
Health Technology
|
| O: 0.11%
H: 2.24%
C: 1.03%
results phase 3
Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema
Published: 2021-11-18 (Crawled : 20:00) - biospace.com/
IONS | $41.585 0.08% 0.08% 1.1M
|
Health Technology
|
| O: 3.11%
H: 0.84%
C: -4.03%
ema phase 3 hereditary angioedema
Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia
Published: 2021-11-02 (Crawled : 12:00) - biospace.com/
IONS | $41.585 0.08% 0.08% 1.1M
|
Health Technology
|
| O: 4.68%
H: 0.78%
C: -0.99%
phase 3
Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
Published: 2021-10-17 (Crawled : 00:00) - prnewswire.com
IONS | $41.585 0.08% 0.08% 1.1M
|
Health Technology
|
| O: -6.67%
H: 0.7%
C: -8.03%
phase 3 als
Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)
Published: 2021-09-15 (Crawled : 12:15) - biospace.com/
IONS | $41.585 0.08% 0.08% 1.1M
|
Health Technology
|
| O: -0.58%
H: 4.44%
C: 2.67%
BIIB | $195.16 -0.83% -0.85% 870K
|
Health Technology
|
| O: 1.03%
H: 1.15%
C: 0.07%
potential phase 3
Non-profit Partnership Spurs Phase 3 Clinical Trial for Patients With Rare Genetic Form Of ALS
Published: 2021-04-08 (Crawled : 12:00) - biospace.com/
IONS | $41.585 0.08% 0.08% 1.1M
|
Health Technology
|
| O: -0.23%
H: 0.37%
C: -1.97%
partnership genetic phase 3 trial als rare
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Published: 2021-04-05 (Crawled : 12:00) - prnewswire.com
IONS | $41.585 0.08% 0.08% 1.1M
|
Health Technology
|
| O: 0.6%
H: 3.61%
C: 3.35%
phase 3 trial als
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.